The study harnesses the power of cutting-edge single-cell technologies and advanced computational methodologies to dissect the complexities of hematopoiesis at unprecedented resolution. By combining distinct analytical platforms—such as CITE-seq, TEA-seq, and InfinityFlow—the researchers constructed a comprehensive schematic that captures not only cell surface markers and transcriptomic landscapes but also chromatin accessibility and high-dimensional flow cytometric data. This synthesis of disparate modalities enables a multi-layered view of marrow progenitor cells, illuminating the dynamic and discrete states through which hematopoietic cells transit as they commit to specialized lineages.

Central to the study’s findings is a challenge to the long-standing “continuum” model of hematopoiesis. Contrary to the notion that progenitor cells gradually and smoothly transition along a developmental spectrum, the data instead reveal that cells occupy distinct “buckets” or discrete states characterized by specific transcriptional programs. These states serve as critical regulatory nodes, orchestrated by complex gene regulatory networks that modulate the progression from multipotency to lineage commitment. This refined model captures the stepwise and stable transitions underpinning differentiation, bringing into focus developmental crossroads where cellular fate is decisively determined.

A striking breakthrough in this research is the identification of a previously unappreciated set of rare progenitors designated as “MultiLin” cells. These cells are pivotal players in hematopoiesis, representing the last multipotent progenitor stage before irreversible lineage restriction. Unlike classical progenitor definitions, MultiLin cells possess a unique transcriptional and regulatory signature that equips them to give rise to a broad spectrum of mature blood cells, including erythroid, myeloid, eosinophil, basophil, and mast cells. Their capability to dynamically respond to physiological stresses such as parasitic infections highlights a sophisticated adaptive dimension of marrow biology that could be exploited therapeutically.

The researchers employed a novel computational strategy to unravel the gene regulatory networks controlling these states. By interrogating transcription factor (TF) activity with base-pair resolution within accessible chromatin regions, they deciphered how specific TFs influence extensive gene expression programs that drive cells toward lineage commitment or preservation of multipotency. This granular mapping of TF engagement provides an essential framework for understanding the molecular hierarchies guiding hematopoiesis, making it possible to predict and eventually manipulate these trajectories for clinical applications.

The significance of this multimodal integrative framework transcends hematopoiesis. According to Dr. H. Leighton “Lee” Grimes, the principal investigator, this approach could serve as a blueprint for elucidating developmental hierarchies across diverse complex tissues, including solid organs and tumors. The capacity to delineate discrete cell states and their regulatory underpinnings holds promise not only for stem cell biology but also for regenerative medicine and oncology, where cell fate determination is often disrupted.

Importantly, the expanded resolution and scope afforded by combining surface protein profiling, chromatin landscape analysis, and high-throughput flow cytometry enable an unprecedented ability to isolate and characterize rare cell populations that traditional methods might overlook. Such precision paves the way for targeted isolation of therapeutically relevant progenitors or malignant subsets, facilitating the development of interventions that are fine-tuned to specific cellular contexts and gene programs.

Moving forward, one of the critical steps outlined by the research team is the translation of insights gained from murine models to human biology. While murine hematopoiesis has served as a foundational system for decades, the adaptation of this unified single-cell multi-omics approach to human bone marrow samples is essential for clinically relevant discoveries. Achieving this will demand overcoming challenges related to tissue accessibility, variability, and scaling but holds transformative potential for personalized medicine.

The implications of this research extend into stem cell engineering, where understanding and recreating natural developmental programs in vitro has been a long-standing goal. This discrete state model sets the stage for more accurately recapitulating hematopoietic differentiation pathways, thereby improving the efficiency and fidelity of laboratory-grown blood cells. Such advances could revolutionize treatments for congenital blood disorders, increase the availability of transfusable cells, and bolster cell-based immunotherapies.

Furthermore, the integrative approach underscores the utility of applying comprehensive computational tools to biological data—a necessity when dissecting complex systems with overlapping and dynamic regulatory layers. By combining dimensionality reduction techniques, imputation algorithms, and high-resolution TF binding analysis, the study provides a template for future research aiming to decode cellular heterogeneity and plasticity, whether in developmental biology or disease contexts.

The research was supported by grants from the National Institutes of Health and benefitted from collaboration with Cytek Biosciences, which provided advanced cytometry services. The multi-institutional team exemplifies the kind of interdisciplinary effort—melding bioinformatics, molecular biology, and clinical expertise—required to solve pressing biomedical puzzles.

This study pulls back the curtain on the cellular choreography of blood formation with a clarity and detail that were previously unreachable. It not only refines our conceptual frameworks in hematopoiesis but also offers tangible technological and biological tools to accelerate the development of next-generation cancer treatments and regenerative therapies. By exposing the discrete states that govern stem cell hierarchies, this novel framework heralds a new chapter in understanding life’s fundamental processes and translates them into medical breakthroughs.

Subject of Research: Cells

Article Title: A unified multimodal single-cell framework reveals a discrete state model of hematopoiesis in mice

News Publication Date: 22-Oct-2025

Web References:
https://www.nature.com/articles/s41590-025-02307-3
https://altanalyze.org/MarrowAtlas/

Image Credits: Cincinnati Children’s

Keywords: Health and medicine, Biomedical engineering, Cell biology, Computational biology, Developmental biology, Immunology

Dr. Speck’s recognition stems from her seminal research elucidating the complex processes underpinning hematopoiesis, the biological mechanism through which blood cells are formed, and leukemogenesis, the pathological progression that leads to leukemia. Her discoveries have enhanced the scientific community’s understanding of how blood cells develop and how mutations can derail this process, leading to malignancies. Central to her work is the identification and characterization of the transcription factor complex known as core binding factor (CBF), a critical regulator of embryonic blood cell development. The complex includes the RUNX1 subunit, encoded by the RUNX1 gene, mutations in which have been linked to familial platelet disorder with predisposition to myeloid malignancies, a hereditary condition increasing susceptibility to blood cancers such as myelodysplastic syndromes and leukemia.

The core binding factor complex functions as a master regulator orchestrating gene expression during hematopoietic differentiation. RUNX1, in particular, acts as a gatekeeper ensuring proper lineage specification and maturation of hematopoietic stem and progenitor cells. Disruption of RUNX1 function through genetic mutations induces aberrant transcriptional programs, impairing normal blood formation and predisposing cells to leukemic transformation. Dr. Speck’s work dissecting the molecular roles of CBF and RUNX1 has been instrumental in unraveling the pathobiology of hematologic malignancies, offering critical insights into the mechanisms by which genetic abnormalities can initiate and propagate blood cancers.

Beyond her basic science discoveries, Dr. Speck’s research has broad translational implications. Understanding the molecular pathways governed by CBF and RUNX1 opens avenues for therapeutic intervention in leukemia and related hematologic disorders. By illuminating how transcription factors control both normal and malignant hematopoiesis, her studies provide a foundational framework for developing targeted treatments that could correct or counteract the effects of pathogenic mutations. Such precision medicine approaches hold promise for improving prognosis and treatment efficacy for patients afflicted with myeloid leukemias.

Dr. Speck’s research excellence is complemented by her extensive service to the scientific community. She has been a dedicated reviewer for leading academic journals including Blood, Nature, Nature Genetics, Cell, Stem Cell, Cancer Cell, Science, and the Proceedings of the National Academy of Sciences (PNAS). Furthermore, she has chaired multiple NIH study sections and grant review panels for prominent organizations such as the Leukemia and Lymphoma Society, reflecting her role in shaping hematology research funding priorities at a national level. Her leadership in these roles underscores her influence beyond the laboratory, guiding the trajectory of research funding and scientific inquiry in hematology.

An academic trailblazer, Dr. Speck earned her PhD in biochemistry from Northwestern University in 1983. Her postdoctoral training encompassed retroviral pathogenesis and eukaryotic gene regulation at the world-renowned Whitehead Institute and Massachusetts Institute of Technology (MIT). Her broad expertise in molecular biology and genetics provided a solid foundation for her subsequent groundbreaking investigations. Since joining the University of Pennsylvania in 2008, she has also served as co-leader of the Hematologic Malignancies Program at the Abramson Cancer Center and is an investigator with the Abramson Family Cancer Research Institute, further integrating her basic research with clinical cancer studies.

Her scientific contributions have been recognized through numerous awards throughout her career, including the Leukemia Society of America Scholar Award, the Fogarty International Center Senior Fellow Award, the Henry M. Stratton Medal for Basic Science bestowed by the American Society of Hematology in 2015, and the Donald Metcalf Award from the International Society for Experimental Hematology in 2018. In 2019, she was elected a member of the National Academy of Sciences, reflecting the high esteem in which she is held by her peers in the scientific community. This latest ASH award confirms not only the continued impact of her research but also the enduring relevance of her scientific leadership.

The American Society of Hematology, the organization bestowing this honor, is the world’s largest and most influential professional society dedicated to the study and treatment of blood diseases. Their annual meeting gathers thousands of clinicians and researchers globally, making Dr. Speck’s lecture a highly anticipated highlight. The E. Donnall Thomas Lecture and Prize celebrates those whose pioneering research has fundamentally changed our understanding of hematology, marking a legacy of innovation and discovery that drives progress in blood science.

Dr. Speck’s work has significantly enhanced the biological and clinical understanding of blood cell development and malignancies. Her insights into the genetic and molecular regulation of hematopoiesis have laid the groundwork for novel diagnostic and therapeutic strategies. In doing so, she has helped transform the field, shifting paradigms about how blood disorders—particularly leukemias—originate and evolve. Through her mentorship and scientific rigor, she continues to inspire the next generation of hematology researchers.

Additionally, Dr. Speck’s role as chair of the Department of Cell and Developmental Biology at Penn reflects her broader commitment to fostering academic excellence and interdisciplinary collaboration. Her leadership contributes to advancing biomedical science through integration of basic biology with clinical applications, especially in cancer research. Her capacity to bridge these domains exemplifies the evolving landscape of hematology, where integrated approaches accelerate translation from bench to bedside.

The University of Pennsylvania’s Perelman School of Medicine, where Dr. Speck is based, represents a beacon of biomedical innovation. It is consistently among the nation’s top NIH-funded institutions, supporting a rich environment for pioneering research. Penn Medicine is renowned for its legacy of ‘firsts’ in medical breakthroughs, including cutting-edge therapies like CAR T-cell immunotherapy and advances in mRNA vaccine technology. Dr. Speck’s achievements further contribute to this vibrant ecosystem of discovery and clinical innovation.

In summary, Nancy A. Speck’s receipt of the E. Donnall Thomas Lecture and Prize is a testament to her groundbreaking contributions that have reshaped hematology. Her focused research on transcriptional control mechanisms, particularly through the core binding factor complex and RUNX1, has revealed critical pathways of blood cell development and disease. As hematology moves toward more precise molecular treatments, Dr. Speck’s discoveries serve as foundational knowledge paving the way for future scientific and clinical advancements in fighting blood cancers and related disorders.

Subject of Research: Hematopoiesis, Leukemogenesis, Transcription factor RUNX1, Core binding factor complex
Article Title: Nancy A. Speck, PhD, Honored with the 2025 E. Donnall Thomas Lecture and Prize by the American Society of Hematology
News Publication Date: Not explicitly stated; award is for 2025, with announcement prior to the December 2025 ASH meeting
Web References:
– https://www.med.upenn.edu/apps/faculty/index.php/g275/p8221581
– https://www.hematology.org/newsroom/press-releases/2025/ash-announces-2025-hematologists-honored-with-highest-distinctions
– https://www.hematology.org/awards/honorific/e-donnall-thomas-lecture-and-prize

References: Information derived from University of Pennsylvania and ASH press releases and institutional webpages.
Image Credits: None provided in the source content.

Keywords: Hematology, Hematopoiesis, Blood cancer, Leukemogenesis, RUNX1, Core binding factor, Transcription factors, Leukemia, Myeloid malignancies, Stem cell biology, Molecular hematology, Cancer research